• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Phospholipid regulation of innate immunity and respiratory viral infection.磷脂对先天免疫和呼吸道病毒感染的调节作用。
J Biol Chem. 2019 Mar 22;294(12):4282-4289. doi: 10.1074/jbc.AW118.003229. Epub 2019 Feb 7.
2
Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids.阴离子肺表面活性剂磷脂的抗炎和抗病毒作用。
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jun;1867(6):159139. doi: 10.1016/j.bbalip.2022.159139. Epub 2022 Feb 28.
3
The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids.阴离子肺表面活性剂磷脂的抗炎和抗病毒特性。
Immunol Rev. 2023 Aug;317(1):166-186. doi: 10.1111/imr.13207. Epub 2023 May 5.
4
Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium.阴离子肺表面活性剂脂质治疗抑制人呼吸道上皮细胞感染鼻病毒。
Viruses. 2023 Mar 14;15(3):747. doi: 10.3390/v15030747.
5
Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.肺表面活性剂中的磷脂酰甘油可抑制呼吸道合胞病毒引起的炎症和感染。
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):320-5. doi: 10.1073/pnas.0909361107. Epub 2009 Dec 22.
6
Phosphatidylinositol inhibits respiratory syncytial virus infection.磷脂酰肌醇可抑制呼吸道合胞病毒感染。
J Lipid Res. 2015 Mar;56(3):578-587. doi: 10.1194/jlr.M055723. Epub 2015 Jan 5.
7
Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication.人类 TLR4 在呼吸道合胞病毒诱导的 NF-κB 激活、病毒进入和复制中的作用。
Innate Immun. 2012 Dec;18(6):856-65. doi: 10.1177/1753425912444479. Epub 2012 Apr 25.
8
Structural analogs of pulmonary surfactant phosphatidylglycerol inhibit toll-like receptor 2 and 4 signaling.肺表面活性物质磷脂酰甘油的结构类似物可抑制Toll样受体2和4信号传导。
J Lipid Res. 2016 Jun;57(6):993-1005. doi: 10.1194/jlr.M065201. Epub 2016 Apr 19.
9
Toll-like receptor 4-mediated respiratory syncytial virus disease and lung transcriptomics in differentially susceptible inbred mouse strains.Toll 样受体 4 介导致病性呼吸道合胞病毒病和肺转录组学在不同易感性近交系小鼠中的差异表达。
Physiol Genomics. 2019 Dec 1;51(12):630-643. doi: 10.1152/physiolgenomics.00101.2019. Epub 2019 Nov 18.
10
Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2.阴离子肺表面活性物质磷脂通过结合脂多糖相互作用蛋白CD14和MD-2来抑制肺泡巨噬细胞和U937细胞的炎症反应。
J Biol Chem. 2009 Sep 18;284(38):25488-500. doi: 10.1074/jbc.M109.040832. Epub 2009 Jul 7.

引用本文的文献

1
Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms of Extract Against Respiratory Syncytial Virus.整合代谢组学与网络药理学揭示提取物抗呼吸道合胞病毒的机制
Int J Mol Sci. 2025 May 29;26(11):5244. doi: 10.3390/ijms26115244.
2
SARS-CoV-2 Spike Protein and Long COVID-Part 2: Understanding the Impact of Spike Protein and Cellular Receptor Interactions on the Pathophysiology of Long COVID Syndrome.严重急性呼吸综合征冠状病毒2刺突蛋白与新冠后综合征——第2部分:了解刺突蛋白与细胞受体相互作用对新冠后综合征病理生理学的影响
Viruses. 2025 Apr 25;17(5):619. doi: 10.3390/v17050619.
3
The Therapeutic Potential of Myo-Inositol in Managing Patients with Respiratory Diseases.肌醇在呼吸系统疾病患者管理中的治疗潜力。
Int J Mol Sci. 2025 Feb 28;26(5):2185. doi: 10.3390/ijms26052185.
4
Therapeutic benefits of glycerol in dry eye disease.甘油在干眼病中的治疗益处。
Front Med (Lausanne). 2025 Jan 15;11:1531670. doi: 10.3389/fmed.2024.1531670. eCollection 2024.
5
Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections.Toll样受体4(TLR4)与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的相互作用:揭示2019冠状病毒病(COVID-19)感染中炎症和严重程度的复杂机制
J Inflamm Res. 2024 Jul 26;17:5077-5091. doi: 10.2147/JIR.S474707. eCollection 2024.
6
A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response.一种抑制 SARS-CoV-2 病毒的经典和非经典进入以及内在肺内炎症反应的治疗方法。
Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2408109121. doi: 10.1073/pnas.2408109121. Epub 2024 Jul 19.
7
TLR4 signalling: the key to controlling EV71 replication and inflammatory response.TLR4 信号通路:控制 EV71 复制和炎症反应的关键。
Front Cell Infect Microbiol. 2024 Jun 13;14:1393680. doi: 10.3389/fcimb.2024.1393680. eCollection 2024.
8
Network pharmacology combined with metabolomics to explore the mechanism for Lonicerae Japonicae flos against respiratory syncytial virus.网络药理学结合代谢组学探讨金银花抗呼吸道合胞病毒的作用机制。
BMC Complement Med Ther. 2023 Dec 12;23(1):449. doi: 10.1186/s12906-023-04286-0.
9
Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase.流感病毒感染中的免疫反应和病毒神经氨酸酶对免疫损伤的调节。
Virol J. 2023 Aug 28;20(1):193. doi: 10.1186/s12985-023-02164-2.
10
Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.表面活性物质替代疗法作为 COVID-19 的有前途的治疗方法:更新的叙述性综述。
Biosci Rep. 2023 Aug 31;43(8). doi: 10.1042/BSR20230504.

本文引用的文献

1
Vaccine development for respiratory syncytial virus.呼吸道合胞病毒疫苗的研发
Curr Opin Virol. 2017 Apr;23:107-112. doi: 10.1016/j.coviro.2017.03.012. Epub 2017 May 16.
2
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.呼吸道合胞病毒:感染、检测及预防与治疗的新选择
Clin Microbiol Rev. 2017 Jan;30(1):277-319. doi: 10.1128/CMR.00010-16.
3
Structural analogs of pulmonary surfactant phosphatidylglycerol inhibit toll-like receptor 2 and 4 signaling.肺表面活性物质磷脂酰甘油的结构类似物可抑制Toll样受体2和4信号传导。
J Lipid Res. 2016 Jun;57(6):993-1005. doi: 10.1194/jlr.M065201. Epub 2016 Apr 19.
4
Lung Structure and the Intrinsic Challenges of Gas Exchange.肺结构与气体交换的内在挑战
Compr Physiol. 2016 Mar 15;6(2):827-95. doi: 10.1002/cphy.c150028.
5
Phosphatidylinositol inhibits respiratory syncytial virus infection.磷脂酰肌醇可抑制呼吸道合胞病毒感染。
J Lipid Res. 2015 Mar;56(3):578-587. doi: 10.1194/jlr.M055723. Epub 2015 Jan 5.
6
Recognition of lipopolysaccharide pattern by TLR4 complexes.TLR4 复合物对脂多糖模式的识别。
Exp Mol Med. 2013 Dec 6;45(12):e66. doi: 10.1038/emm.2013.97.
7
Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung.纳米盘作为一种治疗性递药载体:抑制肺部呼吸道合胞病毒感染。
Int J Nanomedicine. 2013;8:1417-27. doi: 10.2147/IJN.S39888. Epub 2013 Apr 15.
8
The TLR4 antagonist Eritoran protects mice from lethal influenza infection.TLR4 拮抗剂 Eritoran 可保护小鼠免受致死性流感感染。
Nature. 2013 May 23;497(7450):498-502. doi: 10.1038/nature12118. Epub 2013 May 1.
9
PAMPs and DAMPs: signal 0s that spur autophagy and immunity.PAMPs 和 DAMPs:刺激自噬和免疫的信号 0。
Immunol Rev. 2012 Sep;249(1):158-75. doi: 10.1111/j.1600-065X.2012.01146.x.
10
Diverse functions of pulmonary collectins in host defense of the lung.肺凝集素在肺部宿主防御中的多种功能。
J Biomed Biotechnol. 2012;2012:532071. doi: 10.1155/2012/532071. Epub 2012 May 20.

磷脂对先天免疫和呼吸道病毒感染的调节作用。

Phospholipid regulation of innate immunity and respiratory viral infection.

机构信息

From the Department of Medicine, Pulmonary Division, National Jewish Health, Denver, Colorado 80206

出版信息

J Biol Chem. 2019 Mar 22;294(12):4282-4289. doi: 10.1074/jbc.AW118.003229. Epub 2019 Feb 7.

DOI:10.1074/jbc.AW118.003229
PMID:30733339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6433062/
Abstract

Toll-like receptors (TLRs) coupled to intracellular signaling cascades function as central elements of innate immunity that control transcription of numerous pro-inflammatory genes. Two minor anionic phospholipids present in the pulmonary surfactant complex, palmitoyl-oleoyl-phosphatidylglycerol (POPG) and phosphatidylinositol (PI), antagonize the cognate ligand activation of TLRs 2 and 4. The lipids block recognition of activating ligands by the TLRs, either directly or via the TLR4 coreceptors CD14 and MD2. Antagonism of TLR activation results in inhibition of the initiating step of the pro-inflammatory signaling pathways. Evidence for this mechanism of action comes from direct binding studies between CD14 and MD2 with POPG and PI. Additional evidence for this mechanism of antagonism also comes from monitoring the reduction of protein phosphorylation events that characterize the intracellular signaling by activated TLRs. The pathogenesis of respiratory syncytial virus (RSV) and influenza A virus (IAV) have been linked to TLR4 activation, and we examined the action of POPG and PI as potential antagonists of the pathology of these viruses. Surprisingly, POPG and PI dramatically curtail infection, in addition to inhibiting inflammatory sequelae associated with RSV and IAV infections. The mechanism of action by the lipids is disruption of virus particle binding to host cell plasma membrane receptors, required for viral uptake. The antagonism of activation of TLRs and virus binding to the alveolar epithelium by resident constituents of the pulmonary surfactant system suggests that POPG and PI function in homeostasis, to prevent inflammatory processes that result in reductions in gas exchange within the alveolar compartment.

摘要

Toll 样受体 (TLRs) 与细胞内信号级联偶联,作为先天免疫的核心元件,控制众多促炎基因的转录。肺表面活性剂复合物中存在的两种少量阴离子磷脂,棕榈酰-油酰-磷脂酰甘油 (POPG) 和磷脂酰肌醇 (PI),拮抗 TLRs 2 和 4 的同源配体激活。这些脂质通过 TLR4 核心受体 CD14 和 MD2 直接或间接阻断 TLR 对激活配体的识别。TLR 激活的拮抗作用导致促炎信号通路的起始步骤受到抑制。这种作用机制的证据来自 CD14 和 MD2 与 POPG 和 PI 之间的直接结合研究。这种拮抗机制的其他证据还来自监测激活 TLR 所特征的蛋白磷酸化事件的减少。呼吸道合胞病毒 (RSV) 和甲型流感病毒 (IAV) 的发病机制与 TLR4 激活有关,我们研究了 POPG 和 PI 作为这些病毒病理的潜在拮抗剂的作用。令人惊讶的是,POPG 和 PI 不仅抑制 RSV 和 IAV 感染相关的炎症后遗症,还显著减少感染。脂质的作用机制是破坏病毒颗粒与宿主细胞膜受体的结合,这是病毒摄取所必需的。肺表面活性剂系统中固有成分对 TLR 激活和病毒与肺泡上皮结合的拮抗作用表明,POPG 和 PI 在维持肺内气体交换平衡方面发挥作用,以防止导致肺泡腔内气体交换减少的炎症过程。